H. Lundbeck, Lundbeck and PAION partner on Phase III compound Desmoteplase for acute stroke

H. Lundbeck A/S and PAION Deutschland GmbH announced today that they have entered into an exclusive partnership agreement for the development and marketing of PAION’s Phase III product Desmoteplase for stroke in Europe, Japan and the rest of the world except the United States (USA) and Canada. Forest Laboratories holds the marketing and development rights in the USA and Canada.